ATRAptarGroup demonstrates solid fundamental performance with consistent profitability and a healthy balance sheet. Thematic tailwinds in essential consumer and pharmaceutical markets provide stability, though recent technical indicators suggest a neutral to cautious short-term outlook.
AptarGroup operates in stable, albeit less dynamic, end markets such as consumer products, beauty, and pharmaceuticals. While these sectors offer resilience, they may not capture the high-growth potential of emerging technology themes.
AptarGroup demonstrates strong financial health with robust profitability, consistent revenue growth, and a well-managed balance sheet. Its valuation metrics are reasonable given its stable market position and earnings performance.
The stock is trading near its recent highs, showing positive momentum over the past month, but some indicators suggest it is approaching resistance levels and could be due for consolidation.
| Factor | Score |
|---|---|
| Consumer Staples & Healthcare Exposure | 85 |
| E-commerce & Direct-to-Consumer Trends | 70 |
| Sustainability & Material Innovation | 75 |
| Limited Exposure to High-Growth Tech | 40 |
| Geographic Diversification | 80 |
| Factor | Score |
|---|---|
| Valuation | 70 |
| Profitability | 75 |
| Growth | 60 |
| Balance Sheet Health | 85 |
| Cash Flow | 90 |
| Dividend Yield | 70 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 50 |
| Support & Resistance | 40 |
| Moving Averages | 80 |
| Volume | 60 |
Consistent Earnings Beats
The company has consistently beaten earnings per share (EPS) estimates for the past several quarters, with surprise percentages ranging from 0.88% to 20.0%. This demonstrates a strong ability to manage operations and meet or exceed financial expectations.
Reasonable Price-to-Earnings (P/E) Ratio
The trailing twelve-month (TTM) P/E ratio is 29.58. While not low, it is within a reasonable range considering the company's market position and historical performance. The P/E for 2024 is 27.5, suggesting a more forward-looking valuation. Further analysis against industry peers is recommended.
High Quarterly P/S Ratio
The quarterly Price-to-Sales (P/S) ratio for Q1 2025 is 11.0, and Q4 2024 is 12.1. These are significantly higher than the annual P/S ratios, suggesting potential overvaluation based on very recent performance or forward expectations that may not materialize.
Slowing Revenue Growth (Year-over-Year)
While annual revenue shows growth, the quarterly revenue figures show a slowdown (e.g., 848.09 million in Q4 2024 compared to 915.45 million in Q1 2024). Further analysis of year-over-year quarterly revenue growth is needed to confirm deceleration.
July 2025
24
Ex-Dividend Date
August 2025
1
Next Earnings Date
H: $1.61
A: $1.59
L: $1.57
H: 961.79M
A: 954.06M
L: 941.50M
August 2025
14
Next Dividend Date
AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, aerosol valves, and digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
175.00 USD
The 39 analysts offering 1 year price forecasts for ATR have a max estimate of 205.00 and a min estimate of 160.00.